Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBridge Biosciences (NBP) Long-Term Investments (2020 - 2023)

NovaBridge Biosciences (NBP) has 4 years of Long-Term Investments data on record, last reported at $1.7 million in Q4 2023.

  • On a quarterly basis, Long-Term Investments fell 61.31% to $1.7 million in Q4 2023 year-over-year; TTM through Dec 2023 was $1.7 million, a 61.31% decrease, with the full-year FY2022 number at $4.5 billion, up 7995.49% from a year prior.
  • Long-Term Investments reached $1.7 million in Q4 2023 per NBP's latest filing, up from $1.6 million in the prior quarter.
  • Over the last five years, Long-Term Investments for NBP hit a ceiling of $55.1 billion in Q4 2021 and a floor of $40892.1 in Q4 2020.
  • A 4-year average of $6.9 billion and a median of $18.4 million in 2022 define the central range for Long-Term Investments.
  • Peak YoY movement for Long-Term Investments: skyrocketed 134678182.77% in 2021, then plummeted 99.99% in 2022.
  • Tracing NBP's Long-Term Investments over 4 years: stood at $40892.1 in 2020, then surged by 134678182.77% to $55.1 billion in 2021, then tumbled by 99.99% to $4.3 million in 2022, then crashed by 61.31% to $1.7 million in 2023.
  • Business Quant data shows Long-Term Investments for NBP at $1.7 million in Q4 2023, $1.6 million in Q2 2023, and $4.3 million in Q4 2022.